BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 PR Newswire SAN RAFAEL, Calif., June 16, 2026 Data from an...